# MaaT Pharma

位于里昂的高多样性微生物生态系统肿瘤学先驱；主导药物 MaaT013 在欧洲进入针对急性移植物抗宿主病的关键 III 期试验，并建有自动化 GMP 工厂。

Source: https://cn.bioecon.ru/companies/maat-pharma/
Updated: 2026-07-01

- 国家: France
- 代码: EPA:ALMAAT

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 2025 年 7 月获得 European Investment Bank（EIB）的 €3750万贷款 | https://www.maatpharma.com/july-28-2025-maat-pharma-secures-e37-5-million-loan-from-european-investment-bank-eib-marking-a-new-step-in-advancing-its-clinical-program-in-hemato-oncology/ |
| 产能 | 每年9,000袋MaaT013和130万粒MaaT033胶囊 | https://www.pharmaceutical-technology.com/projects/maat-pharmas-microbiome-ecosystem-therapies-manufacturing-facility-france/ |
| 监管批准 | Xervyteg（MaaT013）上市许可申请于2025年6月提交；2026年5/6月获得CHMP的负面意见；计划进行复审 | https://www.maatpharma.com/june-2-2025-maat-pharma-advances-toward-commercialization-and-submits-marketing-authorization-application-to-the-european-medicines-agency-ema-for-xervyteg-maat013-in-acute-graft-versus-ho/, https://www.maatpharma.com/june-26-2026-maat-pharma-announces-plan-to-request-re-examination-following-negative-chmp-opinion-for-maat013-for-the-treatment-of-acute-graft-versus-host-disease/ |
| 生产基地 | 位于法国里昂附近圣康坦-法拉维耶的cGMP工厂 | https://www.pharmaceutical-technology.com/projects/maat-pharmas-microbiome-ecosystem-therapies-manufacturing-facility-france/ |
| 营收 | 2025年€450万;2026年第一季度€80万 | https://live.euronext.com/en/products/equities/company-news/2026-03-31-maat-pharma-announces-2025-annual-results-and-provides, https://www.maatpharma.com/may-26-2026-maat-pharma-provides-business-update-and-reports-financial-results-for-the-first-quarter-2026/ |

独立来源: live.euronext.com, pharmaceutical-technology.com

## 技术

- [微生物组治疗药物（活体生物治疗产品）](https://cn.bioecon.ru/technology/microbiome-therapeutics-lbps/)